Healthcare Stocks on the Move – Novadaq Technologies (NASDAQ:NVDQ), Anacor Pharmaceuticals (NASDAQ:ANAC), ISIS Pharmaceuticals (NASDAQ:ISIS)
Houston, TX – April 22, 2013 — (Net PR News) – AnotherWinningTrade.com, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s focus is on: Novadaq Technologies Inc. (NASDAQ:NVDQ), Anacor Pharmaceuticals Inc (NASDAQ:ANAC), ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)
Novadaq Technologies Inc. (NASDAQ:NVDQ) soared to a new high after revealing that it presented interim results from PILLAR™II, Perfusion Assessment in Laparoscopic Left Anterior Resection, during the 2013 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting, which was being held in Baltimore, MD from April 17-20.
How Should Investors Trade NVDQ Now? Don’t Trade NVDQ Until You Read This TREND ANALYSIS REPORT
Novadaq Technologies Inc. (NASDAQ:NVDQ) gained +24.50%, to close at $12.73 and its overall volume in the last trading session was 1.72 million shares, beating the average volume of 482,996. NVDQ hit the day high price of $12.98 and day low of $10.52.
The stock is trading with positive year-to-date performance of +43.36%. The company has total market cap of $512.26 million.
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) marked a new 52-week high on Friday. The stock has reportedly been moving up since quarterly results last month and getting a $22.7 million research grant from the Gates foundation earlier this month.
How Should Investors React To ANAC Now? Find Out In This TREND ANALYSIS REPORT
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) jumped +13.60%, with the closing price of $8.02. The overall volume in the last trading session was 1.43 million shares. Its fifty two week range was $3.00-$8.25. The total market capitalization remained $285.26 million.
The stock is ahead of its 52 week low 167.33% and its last month price volatility remained 9.36% with a target price of $13.00. In its share capital, the company has 36.06 million outstanding shares, while 32.97 million shares have been floated in the market.
It has insider ownership of 0.27% with its institutional ownership at 99.99%. Its current year earnings per share grew -3.08%.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) was another new high achiever after awarding a contract extension to work with Hemostasis Reference Laboratory Inc., a subsidiary of CML HealthCare Inc., on their Factor XI (“ISIS-FXIRX”) Phase II clinical trial.
Get A Free Report And Detailed Analysis On ISIS CLICK HERE To Read
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares went +8.17% up and closed at $21.10 in the last trading session. Its overall traded volume was 3.79 million shares. The stock’s opening price was $19.57, hitting the day high price of $21.27 and day low of $19.57.
ISIS has earnings per share of -$0.65. The company has -12.71% returns on assets, -36.97% returns on equity and its return on investments is -14.88%.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.